Category: Viking Systems Inc.
ConMed closes its 27¢-per-share tender offer for medical imaging company Viking Systems, giving it about 84% of Viking as it looks to close its short-form merger.
ConMed (NSDQ:CNMD) said it's closed its 27¢-per-share tender offer for Viking Systems (OTC:VKNG), leaving it with about 84% of shares in the medical imaging maker.
ConMed agrees to pay 27¢ per share, or $22.5 million, for Viking Systems and its 3D surgical imaging system.
Varian and Siemens sign global radiosurgery collaboration deal; Bausch & Lomb eyes new devices; Keir Surgical signs an exclusive distribution with Viking Systems; Fluoptics lands in Cambridge, Mass.; NxStage CEO Burbank sheds 9.2k shares ; and Baxter finalizes buyout of Sigma International; plus, a Funding Roundup and analysts' ups and downs.
Varian and Siemens sign global radiosurgery collaboration deal
Becton, Dickinson & Co. agrees to sell its BD Biosciences - Discovery Labware unit to Corning Inc. for $730 million; also, Cook launches new biotech arm; Delcath goes Dutch; Positron buys isotope maker; Viking Systems releases Q1 prelims; Premier inks breast-screening deal with NeoMatrix; plus, a Funding Roundup and analysts' ups and downs.
Becton Dickinson & Co. (NYSE:BDX) said it agreed to sell its BD Biosciences - Discovery Labware unit to Corning Inc. (NYSE:GLW) for about $730 million in cash.
Boston Scientific launches its BackStop kidney stone treatment, licensed from Pluromed, in the U.S. and certain international markets; also, Siemens lands 3rd year defense contract worth up to $1.9 billion; Bruker Corp. nabs all shares of SkyScan for an undisclosed amount; Viking expects 40% sales growth for Q1 2012; Smith & Nephew acquires LifeModeler for an undisclosed amount; Wound Care Innovations signs exclusive N.A.
Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.
Covidien is said to be close to inking a $350 million deal for pulmonary diagnostic tool maker superDimension; also, Medtronic files for senior note offering; pSivida inks 2nd evaluation deal for Durasert eye implant; Viking Systems expands China footprint; BioDirection licenses Nanosys nanowire patents; Cameron Health buyout points to med-tech M&A trend; Covidien, Kensey Nash announce dividends; GPOs: Novation, Premier ink new hospital bed, HIT and wound care products; plus, a Funding Roundup and analysts' ups and downs.
Covidien (NYSE:COV) is set to close a $350 million buyout of Israeli lung diagnosis firm superDimension by the end of the week, according to Israeli business journal Calcalist.
Founded in Tel Aviv by Pinchas Gilboa, Minneapolis-based superDimension, which employs about 120 people worldwide, also has offices in Dusseldorf, Germany.
Angeion makes up for sagging European sales by focusing on group purchasing organizations and service revenues in Q1; also, Natus Medical's earnings plunge; Mindray posts big boosts to top, bottom lines; iCad narrows quarterly losses; MiMedx sales soar in 2011; InSite's sales slide, losses widen; Exactech's bottom line shrinks; Viking boosts sales, widens losses; MedPro cuts losses; and Alphatec dives deeper into the red.
Angeion Corp. (NSDQ:ANGN) narrowed its 1st-quarter losses despite flat sales for the 3 months ended Jan. 31.
Although dragged down by a tough European climate, focusing on group purchasing organization and service revenues kept the company's sales from sliding, the cardiorespiratory diagnostic systems maker said.
